All Stories

  1. Photodynamic Therapy Using Talaporfin Sodium and Semiconductor Laser Induces Dose and Time Dependent Cytocidal Effect for Human Glioma Derived Stem Cells

    Article • June 2025, MDPI AG

    Hiroaki Wakimoto

  2. Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy

    Article • Molecular Therapy Oncology, June 2025, Elsevier

    Hiroaki Wakimoto

  3. Engineered allogeneic stem cells orchestrate T lymphocyte–driven immunotherapy in immunosuppressive leptomeningeal brain metastasis

    Article • JNCI Journal of the National Cancer Institute, January 2025, Oxford University Press (OUP)

    Hiroaki Wakimoto

  4. Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes

    Article • Neuro-Oncology Advances, December 2024, Oxford University Press (OUP)

    Hiroaki Wakimoto

  5. Gene expression signatures predict the sensitivity of pediatric brain tumors to different oncolytic viruses

    Article • Molecular Therapy Oncology, September 2024, Elsevier

    Hiroaki Wakimoto

  6. Data from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  7. Data from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  8. Supplemental Figure 1 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  9. Supplemental Figure 1 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  10. Supplemental Figure 2 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  11. Supplemental Figure 2 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  12. Supplemental Figure 3 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  13. Supplemental Figure 3 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • July 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  14. CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

    Article • Clinical Cancer Research, May 2024, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  15. Chimeric oncolytic adenovirus to break away from neutralizing antibodies

    Article • Molecular Therapy, April 2024, Elsevier

    Hiroaki Wakimoto

  16. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

    Article • Journal for ImmunoTherapy of Cancer, April 2024, BMJ

    Hiroaki Wakimoto

  17. Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma

    Article • Cells, March 2024, MDPI AG

    Hiroaki Wakimoto

  18. Exomap1 mouse: A transgenic model for in vivo studies of exosome biology

    Article • Extracellular Vesicle, December 2023, Elsevier

    Hiroaki Wakimoto

  19. PTEN potentiation of oncolytic HSV therapy for glioblastoma

    Article • Molecular Therapy — Oncolytics, June 2023, Elsevier

    Hiroaki Wakimoto

  20. Data from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  21. Data from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  22. Supplementary Figures from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  23. Supplementary Figures from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  24. Supplementary Methods from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  25. Supplementary Methods from Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD<sup>+</sup> to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • April 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  26. Data from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  27. Data from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  28. Data from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  29. Data from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  30. Supplementary Data from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  31. Supplementary Data from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  32. Supplementary Data from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  33. Supplementary Data from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  34. Supplementary Figures from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  35. Supplementary Figures from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  36. Supplementary Table 1 from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  37. Supplementary Table 1 from Local Targeting of NAD<sup>+</sup> Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  38. Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  39. Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  40. Oncolytic virus therapy for malignant gliomas: entering the new era

    Article • Expert Opinion on Biological Therapy, March 2023, Taylor & Francis

    Hiroaki Wakimoto

  41. Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity

    Article • Science Translational Medicine, January 2023, American Association for the Advancement of Science

    Hiroaki Wakimoto

  42. Correlation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery

    Article • Cancers, March 2022, MDPI AG

    Hiroaki Wakimoto

  43. Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice

    Article • Brain Research, January 2022, Elsevier

    Hiroaki Wakimoto

  44. Mutant IDH Inhibitors Induce Lineage Differentiation in IDH-mutant Oligodendroglioma

    Article • November 2021, Cold Spring Harbor Laboratory Press

    Hiroaki Wakimoto

  45. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

    Article • Cells, June 2021, MDPI AG

    Hiroaki Wakimoto

  46. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma

    Article • Cancer Cell, June 2021, Elsevier

    Hiroaki Wakimoto

  47. MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma

    Article • Neuro-Oncology, May 2021, Oxford University Press (OUP)

    Hiroaki Wakimoto

  48. Topography of transcriptionally active chromatin in glioblastoma

    Article • Science Advances, April 2021, American Association for the Advancement of Science

    Hiroaki Wakimoto

  49. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • Cancer Research, April 2021, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  50. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm

    Article • Stem Cells, March 2021, Oxford University Press (OUP)

    Hiroaki Wakimoto

  51. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

    Article • Cell, March 2021, Elsevier

    Hiroaki Wakimoto

  52. Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry

    Article • JCI Insight, January 2021, American Society for Clinical Investigation

    Hiroaki Wakimoto

  53. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, January 2021, Elsevier

    Hiroaki Wakimoto

  54. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma

    Article • Acta Neuropathologica Communications, December 2020, Springer Science + Business Media

    Hiroaki Wakimoto

  55. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma

    Article • Clinical Cancer Research, November 2020, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  56. Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Hiroaki Wakimoto

  57. Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma

    Article • Frontiers in Oncology, November 2020, Frontiers

    Hiroaki Wakimoto

  58. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

    Article • JCO Precision Oncology, November 2020, American Society of Clinical Oncology (ASCO)

    Hiroaki Wakimoto

  59. Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

    Article • Neuro-Oncology, October 2020, Oxford University Press (OUP)

    Hiroaki Wakimoto

  60. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic

    Article • Acta Neuropathologica Communications, October 2020, Springer Science + Business Media

    Hiroaki Wakimoto

  61. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

    Article • Cancer Research, October 2020, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  62. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

    Article • Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  63. High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma

    Article • Frontiers in Oncology, September 2020, Frontiers

    Hiroaki Wakimoto

  64. Sirtuin activation targets IDH-mutant tumors

    Article • Neuro-Oncology, July 2020, Oxford University Press (OUP)

    Hiroaki Wakimoto

  65. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells

    Article • Cancer Discovery, June 2020, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  66. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features

    Article • Acta Neuropathologica, May 2020, Springer Science + Business Media

    Hiroaki Wakimoto

  67. Long-term outcomes of multimodality management for parasagittal meningiomas

    Article • Journal of Neuro-Oncology, February 2020, Springer Science + Business Media

    Hiroaki Wakimoto

  68. Therapeutic Application of PARP Inhibitors in Neuro-Oncology

    Article • Trends in Cancer, February 2020, Elsevier

    Hiroaki Wakimoto

  69. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

    Article • Clinical Cancer Research, January 2020, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  70. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice

    Article • OncoImmunology, January 2020, Taylor & Francis

    Hiroaki Wakimoto

  71. Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma

    Article • Cancer Research, November 2019, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  72. Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling

    Article • Cancers, October 2019, MDPI AG

    Hiroaki Wakimoto

  73. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma

    Article • Oncolytic Virotherapy, October 2019, Taylor & Francis

    Hiroaki Wakimoto

  74. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

    Article • Cell, August 2019, Elsevier

    Hiroaki Wakimoto

  75. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma

    Article • Nature Cell Biology, August 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  76. Glioblastoma: State of the Art and Future Perspectives

    Article • Cancers, July 2019, MDPI AG

    Hiroaki Wakimoto

  77. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

    Article • Nature Biotechnology, July 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  78. A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma

    Article • Targeted Oncology, July 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  79. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

    Article • Nature Communications, July 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  80. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases

    Article • Neuro-Oncology, June 2019, Oxford University Press (OUP)

    Hiroaki Wakimoto

  81. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

    Article • Molecular Therapy — Oncolytics, June 2019, Elsevier

    Hiroaki Wakimoto

  82. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application

    Article • Expert Opinion on Biological Therapy, May 2019, Taylor & Francis

    Hiroaki Wakimoto

  83. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

    Article • Clinical Cancer Research, April 2019, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  84. Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer

    Article • Journal of Clinical Investigation, April 2019, American Society for Clinical Investigation

    Hiroaki Wakimoto

  85. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases

    Article • Clinical Cancer Research, February 2019, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  86. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

    Article • Scientific Reports, January 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  87. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest

    Article • January 2019, Springer Science + Business Media

    Hiroaki Wakimoto

  88. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma

    Article • Clinical Cancer Research, November 2018, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  89. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency–Mediated Acquired Resistance to Temozolomide

    Article • Molecular Cancer Therapeutics, September 2018, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  90. Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center

    Article • Journal of Neuro-Oncology, September 2018, Springer Science + Business Media

    Hiroaki Wakimoto

  91. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

    Article • Acta Neuropathologica, August 2018, Springer Science + Business Media

    Hiroaki Wakimoto

  92. Genotype-targeted local therapy of glioma

    Article • Proceedings of the National Academy of Sciences, August 2018, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  93. Emerging Medical Treatments for Meningioma in the Molecular Era

    Article • Biomedicines, August 2018, MDPI AG

    Hiroaki Wakimoto

  94. CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors

    Article • Science Translational Medicine, July 2018, American Association for the Advancement of Science

    Hiroaki Wakimoto

  95. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells

    Article • Journal of Virology, May 2018, ASM Journals

    Samuel Rabkin, Hiroaki Wakimoto

  96. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models

    Article • Clinical Cancer Research, March 2018, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  97. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Christian Thiede, Hiroaki Wakimoto

  98. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

    Article • Neuro-Oncology, November 2017, Oxford University Press (OUP)

    Hiroaki Wakimoto

  99. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma

    Article • Cancer Cell, October 2017, Elsevier

    Hiroaki Wakimoto

  100. Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models

    Article • International Journal of Cancer, August 2017, Wiley

    Hiroaki Wakimoto

  101. IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy

    Article • Neurosurgery, August 2017, Wolters Kluwer Health

    Hiroaki Wakimoto

  102. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis

    Article • Neuro-Oncology, July 2017, Oxford University Press (OUP)

    Hiroaki Wakimoto

  103. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus

    Article • International Journal of Cancer, July 2017, Wiley

    Hiroaki Wakimoto

  104. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas

    Article • Proceedings of the National Academy of Sciences, July 2017, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  105. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion–Mediated Cytotoxicity

    Article • Cancer Research, June 2017, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  106. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq

    Article • Science, March 2017, American Association for the Advancement of Science

    Hiroaki Wakimoto

  107. Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma

    Article • JNCI Journal of the National Cancer Institute, February 2017, Oxford University Press (OUP)

    Hiroaki Wakimoto

  108. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance

    Article • Cell Stem Cell, February 2017, Elsevier

    Hiroaki Wakimoto

  109. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models

    Article • Neuro-Oncology, January 2017, Oxford University Press (OUP)

    Rami Kantar, Hiroaki Wakimoto

  110. Oncolytic herpes simplex virus interactions with the host immune system

    Article • Current Opinion in Virology, December 2016, Elsevier

    Hiroaki Wakimoto

  111. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

    Article • Clinical Cancer Research, April 2016, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  112. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

    Article • Proceedings of the National Academy of Sciences, April 2016, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  113. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

    Article • Cancer Research, March 2016, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  114. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus

    Article • Neuro-Oncology, March 2016, Oxford University Press (OUP)

    Hiroaki Wakimoto

  115. At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology

    Article • Cancer Research, February 2016, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  116. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

    Article • Cancer Cell, December 2015, Elsevier

    Hiroaki Wakimoto

  117. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells

    Article • Gene Therapy, July 2015, Nature

    Rutger Balvers, Hiroaki Wakimoto

  118. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment

    Article • Journal of Neuropathology & Experimental Neurology, July 2015, Oxford University Press (OUP)

    Hiroaki Wakimoto

  119. The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma

    Article • Molecular Therapy, July 2015, Elsevier

    Hiroaki Wakimoto

  120. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

    Article • Science, January 2015, American Association for the Advancement of Science

    Hiroaki Wakimoto

  121. Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy

    Article • Molecular Therapy, January 2015, Elsevier

    Hiroaki Wakimoto

  122. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma

    Article • Journal of Neuro-Oncology, September 2014, Springer Science + Business Media

    Hiroaki Wakimoto

  123. Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression

    Article • Cancer Discovery, August 2014, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  124. Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma

    Article • Viruses, August 2014, MDPI AG

    Rutger Balvers, Hiroaki Wakimoto

  125. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

    Article • Frontiers in Microbiology, June 2014, Frontiers

    Hiroaki Wakimoto

  126. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

    Article • Science, June 2014, American Association for the Advancement of Science

    Hiroaki Wakimoto

  127. Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy

    Article • JNCI Journal of the National Cancer Institute, May 2014, Oxford University Press (OUP)

    Hiroaki Wakimoto

  128. Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

    Article • Clinical Cancer Research, April 2014, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  129. Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells

    Article • Cell, April 2014, Elsevier

    Hiroaki Wakimoto

  130. Immunovirotherapy for glioblastoma

    Article • Cell Cycle, November 2013, Taylor & Francis

    Hiroaki Wakimoto

  131. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy

    Article • Journal of Neurosurgery, November 2013, Journal of Neurosurgery Publishing Group (JNSPG)

    Dr. Takahiro Ogishima, Dr Masaru Aoyagi, Dr. Kikuo Ohno, Masaaki Yamamoto, Hiroaki Wakimoto

  132. Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models

    Article • Neoplasia, June 2013, Elsevier

    Hiroaki Wakimoto

  133. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

    Article • Proceedings of the National Academy of Sciences, May 2013, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  134. An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma

    Article • Cell Reports, May 2013, Elsevier

    Hiroaki Wakimoto

  135. Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors

    Article • Molecular Therapy, January 2013, Elsevier

    Hiroaki Wakimoto

  136. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects

    Article • Proceedings of the National Academy of Sciences, September 2012, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  137. Expression of FMS-like Tyrosine Kinase 3 Ligand by Oncolytic Herpes Simplex Virus Type I Prolongs Survival in Mice Bearing Established Syngeneic Intracranial Malignant Glioma

    Article • Neurosurgery, September 2012, Wolters Kluwer Health

    Hiroaki Wakimoto

  138. Polo‐Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice

    Article • Stem Cells, May 2012, Oxford University Press (OUP)

    Dr Stephen Yip , Hiroaki Wakimoto

  139. Effect of γ34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain Tumors

    Article • Journal of Virology, February 2012, ASM Journals

    Hiroaki Wakimoto

  140. Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells

    Article • JNCI Journal of the National Cancer Institute, December 2011, Oxford University Press (OUP)

    Hiroaki Wakimoto

  141. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells

    Article • Neuro-Oncology, November 2011, Oxford University Press (OUP)

    Hiroaki Wakimoto

  142. Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts

    Article • Clinical Cancer Research, October 2011, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  143. YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth

    Article • Cancer Research, July 2011, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  144. A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells

    Article • Clinical Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  145. A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models

    Article • Cancer Research, November 2010, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  146. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation

    Article • Journal of Neurosurgery, August 2010, Journal of Neurosurgery Publishing Group (JNSPG)

    Dr Masaru Aoyagi, Masaaki Yamamoto, Hiroaki Wakimoto

  147. TWIST1 promotes invasion through mesenchymal change in human glioblastoma

    Article • Molecular Cancer, July 2010, Springer Science + Business Media

    Hiroaki Wakimoto

  148. Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  149. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

    Article • Future Oncology, April 2010, Future Medicine

    Hiroaki Wakimoto

  150. Directed evolution of adeno-associated virus for glioma cell transduction

    Article • Journal of Neuro-Oncology, July 2009, Springer Science + Business Media

    Hiroaki Wakimoto

  151. Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors

    Article • Cancer Research, April 2009, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  152. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy

    Article • Proceedings of the National Academy of Sciences, March 2009, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  153. Malignant lymphoma presented as left trigeminal neuralgia

    Article • Rinsho Shinkeigaku, January 2009, Societas Neurologica Japonica

    Hiroaki Wakimoto

  154. Herpes Simplex Virus Us3(−) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt–Targeting Molecular Therapeutics

    Article • Clinical Cancer Research, October 2007, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  155. Malignant transformation eight years after removal of a benign epidermoid cyst: a case␣report

    Article • Journal of Neuro-Oncology, April 2006, Springer Science + Business Media

    Hiroaki Wakimoto

  156. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

    Article • Gene Therapy, January 2006, Springer Science + Business Media

    Hiroaki Wakimoto

  157. Usefulness ofl-[methyl-11C] methionine—positron emission tomography as a biological monitoring tool in the treatment of glioma

    Article • Journal of Neurosurgery, September 2005, Journal of Neurosurgery Publishing Group (JNSPG)

    Hiroaki Wakimoto

  158. The Combination of Adenoviral HSV TK Gene Therapy and Radiation is Effective in Athymic Mouse Glioblastoma Xenografts without Increasing Toxic Side Effects

    Article • Journal of Neuro-Oncology, March 2004, Springer Science + Business Media

    Dr Fernando Siller, Hiroaki Wakimoto

  159. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

    Article • Gene Therapy, January 2004, Springer Science + Business Media

    Hiroaki Wakimoto

  160. Impairment of Both Apoptotic and Cytoprotective Signalings in Glioma Cells Resistant to the Combined Use of Cisplatin and Tumor Necrosis Factor α

    Article • Clinical Cancer Research, January 2004, American Association for Cancer Research (AACR)

    Hiroaki Wakimoto

  161. Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study

    Article • Gene Therapy, July 2003, Springer Science + Business Media

    Hiroaki Wakimoto

  162. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

    Article • Gene Therapy, May 2003, Springer Science + Business Media

    Hiroaki Wakimoto

  163. Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels

    Article • Journal of Experimental Therapeutics and Oncology, March 2002, Wiley

    Hiroaki Wakimoto

  164. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors

    Article • Cancer Gene Therapy, March 2002, Springer Science + Business Media

    Hiroaki Wakimoto

  165. The Complement Response Against an Oncolytic Virus Is Species-Specific in Its Activation Pathways

    Article • Molecular Therapy, March 2002, Elsevier

    Hiroaki Wakimoto

  166. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas

    Article • Clinical Neurology and Neurosurgery, April 2001, Elsevier

    Hiroaki Wakimoto

  167. Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant

    Article • Journal of Virology, May 2000, ASM Journals

    Hiroaki Wakimoto

  168. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

    Article • Nature Reports Stem Cells, August 1999, Springer Science + Business Media

    Hiroaki Wakimoto

  169. P53 Overexpression and Proliferative Potential in Malignant Meningiomas

    Article • Acta Neurochirurgica, January 1999, Springer Science + Business Media

    Hiroaki Wakimoto

  170. Recurrence in meningeal hemangiopericytomas

    Article • Surgical Neurology, December 1998, Elsevier

    Hiroaki Wakimoto

  171. DECREASE IN ELASTIN GENE EXPRESSION AND PROTEIN SYNTHESIS IN FIBROBLASTS DERIVED FROM CARDINAL LIGAMENTS OF PATIENTS WITH PROLAPSUS UTERI

    Article • Cell Biology International, September 1997, Wiley

    Hiroaki Wakimoto

  172. Modulation of Motility and Proliferation of Glioma Cells by Hepatocyte Growth Factor

    Article • Japanese Journal of Cancer Research, June 1997, Wiley

    Hiroaki Wakimoto

  173. Efficient Retrovirus-mediated Cytokine-gene Transduction of Primary-cultured Human Glioma Cells for Tumor Vaccination Therapy

    Article • Japanese Journal of Cancer Research, March 1997, Wiley

    Hiroaki Wakimoto

  174. Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors

    Article • Gastroenterology, November 1996, Elsevier

    Hiroaki Wakimoto

  175. Augmented Antitumor Effects of Killer Cells Induced by Tumor Necrosis Factor Gene-Transduced Autologous Tumor Cells from Gastrointestinal Cancer Patients

    Article • Human Gene Therapy, October 1996, Mary Ann Liebert Inc

    Hiroaki Wakimoto

  176. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection.

    Article • Proceedings of the National Academy of Sciences, August 1996, Proceedings of the National Academy of Sciences

    Hiroaki Wakimoto

  177. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas

    Article • Cancer, January 1996, Wiley

    Hiroaki Wakimoto

  178. In VivoAntitumor Effect of Cytotoxic T Lymphocytes Engineered to Produce Interferon-γ by Adenovirus-Mediated Genetic Transduction

    Article • Biochemical and Biophysical Research Communications, January 1996, Elsevier

    Hiroaki Wakimoto

  179. Immunohistochemical Detection of Ki-67 in Replicative Smooth Muscle Cells of Rabbit Carotid Arteries After Balloon Denudation

    Article • Stroke, December 1995, Wolters Kluwer Health

    Hiroaki Wakimoto

  180. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction

    Article • Journal of Cancer Research and Clinical Oncology, September 1995, Springer Science + Business Media

    Hiroaki Wakimoto

  181. Immunohistochemical Detection of Progesterone Receptors and the Correlation with Ki-67 Labeling Indices in Paraffin-embedded Sections of Meningiomas

    Article • Neurosurgery, September 1995, Wolters Kluwer Health

    Hiroaki Wakimoto

  182. Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432

    Article • Medical Oncology, March 1995, Springer Science + Business Media

    Hiroaki Wakimoto

  183. Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of the amphotropic receptor, GLVR-2

    Article • Nucleic Acids Research, January 1995, Oxford University Press (OUP)

    Hiroaki Wakimoto